Key Points
- On March 9 CEO Claire Mazumdar sold 36,766 shares at an average price of $19.17 for a total of $704,804.22, reducing her ownership by 9.77% to 339,392 shares (valued at about $6.51M).
- Bicara (NASDAQ:BCAX) trades near $19.77 with a 52‑week range of $7.80–$20.25 and a market cap of roughly $1.08B, and analysts have a consensus "Moderate Buy" with an average price target of $28.33.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 36,766 shares of the firm's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the transaction, the chief executive officer directly owned 339,392 shares of the company's stock, valued at approximately $6,506,144.64. This trade represents a 9.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Claire Mazumdar also recently made the following trade(s):
- On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total transaction of $71,568.75.
- On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total transaction of $49,278.63.
- On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.
Bicara Therapeutics Stock Performance
NASDAQ:BCAX traded down $0.13 during mid-day trading on Thursday, hitting $19.77. The company had a trading volume of 13,459 shares, compared to its average volume of 500,445. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $20.25. The firm has a market cap of $1.08 billion, a P/E ratio of -8.76 and a beta of -0.78. The business's fifty day moving average is $16.67 and its two-hundred day moving average is $15.96.
Institutional Investors Weigh In On Bicara Therapeutics
A number of large investors have recently bought and sold shares of the stock. Bleakley Financial Group LLC bought a new stake in shares of Bicara Therapeutics during the third quarter worth about $481,000. Schroder Investment Management Group lifted its position in Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company's stock valued at $3,951,000 after acquiring an additional 383,681 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in Bicara Therapeutics by 160.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company's stock valued at $922,000 after acquiring an additional 61,201 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in Bicara Therapeutics during the 2nd quarter valued at about $3,742,000. Finally, SCS Capital Management LLC purchased a new stake in shares of Bicara Therapeutics in the second quarter worth approximately $496,000.
Wall Street Analysts Forecast Growth
BCAX has been the subject of several research reports. UBS Group restated a "buy" rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. BTIG Research reaffirmed a "buy" rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an "outperform" rating on the stock. Finally, Mizuho upgraded shares of Bicara Therapeutics to a "hold" rating in a research note on Thursday, December 18th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $28.33.
Get Our Latest Report on Bicara Therapeutics
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
